Ontx Buy Or Sell . A total of 1 analyst(s) rate the stock as a hold, 2 recommend ontx as a buy and 0 give it an overweight rating. According to the issued ratings of 2 analysts in the last year, the consensus rating for onconova therapeutics stock is buy based on the current 2 buy ratings for ontx.
Sterling Silver and Black Onyx Teardrop Earrings Escape from madeit.com.au
A total of 1 analyst(s) rate the stock as a hold, 2 recommend ontx as a buy and 0 give it an overweight rating. The last trade was done 103 days ago by lederman seth who bough 12 thousand shares. Here's the list of the top best forex brokers in 2021.
Sterling Silver and Black Onyx Teardrop Earrings Escape
Premkumar reddy on december 22, 1998 and is. There are currently 3 hold ratings and 2 buy ratings for the stock. Rigosertib oral, which is phase ii. Nasdaqcm:ontx debt to equity history december 6th 2021.
Source: madeit.com.au
Check Details
Ontx has been the subject of several research reports. There are currently 3 hold ratings and 2 buy ratings for the stock. For example, a price above its moving average is generally considered an upward trend or a buy. Here's the list of the top best forex brokers in 2021. Ad to choose the right forex broker according to your.
Source: www.fnewsbulletin.com
Check Details
Here's the list of the top best forex brokers in 2021. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock. You'll find the onconova therapeutics share forecasts, stock quote and buy / sell signals below. According to present data onconova therapeutics's ontx shares and potentially its.
Source: best-trading-indicator.com
Check Details
58 rows insiders have sold a total of 527,863 onconova therapeutics shares in. A total of 1 analyst(s) rate the stock as a hold, 2 recommend ontx as a buy and 0 give it an overweight rating. (nasdaq:ontx) 5 wall street research analysts have issued “buy,” “hold,” and “sell” ratings for onconova therapeutics in the last twelve months. Its products.
Source: www.redfin.com
Check Details
Nasdaqcm:ontx debt to equity history december 6th 2021. Strong sell candidate unchanged insiders are very positive buying more shares than they are selling in tonix pharmaceuticals holding corp. Its products include rigosertib intravenous (iv) that is in phase iii trials for higher risk myelodysplastic syndromes (mds); (nasdaq:ontx) 5 wall street research analysts have issued “buy,” “hold,” and “sell” ratings for.
Source: lovewordssss.blogspot.com
Check Details
According to the issued ratings of 2 analysts in the last year, the consensus rating for onconova therapeutics stock is buy based on the current 2 buy ratings for ontx. The company was founded by ramesh kumar and e. Only one analyst has given the target price of $2.10 to ontx, which is a premium of 73 percent over the..
Source: pennystocks.com
Check Details
Get a free detailed ontx analysis report. Onconova therapeutics has received a consensus rating of buy. Rigosertib oral, which is phase ii. One analyst has a buy rating, while the other rates ontx as a hold or some equivalent. According to present data onconova therapeutics's ontx shares and potentially its market environment have been in a bullish cycle in the.
Source: www.pinterest.com
Check Details
Onconova therapeutics has received a consensus rating of buy. According to analysts' consensus price target of $11.50, onconova therapeutics has a forecasted upside of 400.0% from its current price of $2.30. Use the zacks rank and style scores to find out is ontx is right for your portfolio. A symbol will be given one of the following overall ratings: Strong.
Source: priceseries.news
Check Details
According to analysts' consensus price target of $11.50, onconova therapeutics has a forecasted upside of 400.0% from its current price of $2.30. There are currently 3 hold ratings and 2 buy ratings for the stock. Strong sell candidate unchanged insiders are very positive buying more shares than they are selling in tonix pharmaceuticals holding corp. A symbol will be given.
